Cabel,

I first started following Resverlogix back when RVX-208 (aka apabetalone) was being pursued as a novel molecule to raise apo-AI, HDL particle number, HDL-cholesterol and promote reverse cholesterol transport......all to battle cardiovascular diseases. Big opportunity since there is unmet need for drugs in this space (especially in high risk patients). As you know, the story has evolved over the years. CETP failures. Challenges to the HDL hypothesis. Appreciation that apabetalone is a bromodomain-2 selective BET inhibitor. Trial successes (i.e. ASSERT, SUSTAIN) and trial failures (i.e ASSURE). Post-hoc analyses identifying potential synergy with rosuvastatin and identifying MACE as an endpoint and identifying responder populations (i.e. diabetes, low-HDL, elevated hsCRP, elevated alkaline phosphatase, etc), and identifying new indications (i.e. renal/CKD, complement/PNH, Fabry, etc....see Golfyeti's response). I've written on much of this in the past in this Evolution of Apabetalone post. Way too much to summarize again here. If you desire more info/background, I suggest you do some serious due diligence by looking at publications, posters, corporate presentations, conference presentations, analyst reports, forum posts, etc. The link library is a good place to start.

BDAZ